

**In the Claims:**

Please amend the claims as follows:

---

1. (original) An isolated polypeptide, wherein said polypeptide is from about 5 to about 71 amino acids in length and comprises a contiguous amino acid sequence  $DX_1CX_2D$ ; wherein  $X_1$  and  $X_2$  are selected from the group consisting of amino acids.
2. (original) The isolated polypeptide of claim 1, wherein  $X_1$  is a valine or a conservatively modified variant thereof.
3. (original) The isolated polypeptide of claim 1, wherein  $X_2$  is a glutamine or a conservatively modified variant thereof.
4. (currently amended) The isolated polypeptide of claim 1, wherein said polypeptide comprises the contiguous amino acid sequence DVCQD (SEQ ID NO: 28).
5. (original) The isolated polypeptide of claim 1, wherein said peptide is a peptidomimetic of  $DX_1CX_2D$ , wherein  $X_1$  and  $X_2$  are selected from the group consisting of amino acids.
6. (original) The isolated polypeptide of claim 1, wherein said polypeptide specifically binds to an antibody raised against Saposin B.
7. (original) The isolated polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence substantially identical to that shown in SEQ ID NO:1 beginning at position 7.
8. (original) The isolated polypeptide of claim 1, wherein said polypeptide comprises at least 5 contiguous amino acids, or conservatively modified variants thereof, said contiguous amino acids having an amino acid sequence as shown in SEQ ID NO:1, beginning at position 7.

9. (currently amended) The isolated polypeptide of claim 1, wherein said polypeptide comprises R-DVCQD-R' (SEQ ID NO: 44); wherein R is from 0 to about 6 contiguous amino acids; and wherein R' is from 0 to about 59 contiguous amino acids.

10. (original) The isolated polypeptide of claim 1 wherein said polypeptide is glycosylated.

11. (currently amended) The isolated polypeptide of claim 1, wherein said polypeptide comprises R-XDVCQD-R' (SEQ ID NO: 45); wherein R is selected from the group consisting of Aa<sub>1</sub>-Aa<sub>2</sub>-Aa<sub>3</sub>-Aa<sub>4</sub>-Aa<sub>5</sub>, Aa<sub>2</sub>-Aa<sub>3</sub>-Aa<sub>4</sub>-Aa<sub>5</sub>, Aa<sub>3</sub>-Aa<sub>4</sub>-Aa<sub>5</sub>, Aa<sub>4</sub>-Aa<sub>5</sub> and Aa<sub>5</sub>, and wherein Aa<sub>1</sub>, Aa<sub>2</sub>, Aa<sub>3</sub>, Aa<sub>4</sub> and Aa<sub>5</sub> are selected from the group consisting of amino acids; X is selected from the group consisting of G, A, S and T; and wherein R' is from 0 to about 59 contiguous amino acids.

12. (original) The isolated polypeptide of claim 11, wherein Aa<sub>1</sub> is a glutamine or a conservative substitution thereof.

13. (original) The isolated polypeptide of claim 11, wherein Aa<sub>2</sub> is a proline or a conservative substitution thereof.

14. (original) The isolated polypeptide of claim 11, wherein Aa<sub>3</sub> is a lysine or a conservative substitution thereof.

15. (original) The isolated polypeptide of claim 11, wherein Aa<sub>4</sub> is an aspartic acid or a conservative substitution thereof.

16. (original) The isolated polypeptide of claim 11, wherein Aa<sub>5</sub> is a asparagine or a conservative substitution thereof.

17. (original) The isolated polypeptide of claim 11, wherein R' is selected from the group consisting of Aa<sub>12</sub>-Aa<sub>13</sub>-Aa<sub>14</sub>-Aa<sub>15</sub>-Aa<sub>16</sub>, Aa<sub>12</sub>-Aa<sub>13</sub>-Aa<sub>14</sub>-Aa<sub>15</sub>, Aa<sub>12</sub>-Aa<sub>13</sub>-Aa<sub>14</sub>, Aa<sub>12</sub>-Aa<sub>13</sub> and Aa<sub>12</sub>, wherein Aa<sub>12</sub>, Aa<sub>13</sub>, Aa<sub>14</sub>, Aa<sub>15</sub> and Aa<sub>16</sub> are selected from the group consisting of amino acids.

18. (original) The isolated polypeptide of claim 17, wherein Aa<sub>12</sub> is a cysteine or a conservative substitution thereof.

19. (original) The isolated polypeptide of claim 17, wherein Aa<sub>13</sub> is an isoleucine or a conservative substitution thereof.

20. (original) The isolated polypeptide of claim 17 wherein Aa<sub>14</sub> is an glutamine or a conservative substitution thereof.

21. (original) The isolated polypeptide of claim 17, wherein Aa<sub>15</sub> is an methionine or a conservative substitution thereof.

22. (original) The isolated polypeptide of claim 17, wherein Aa<sub>16</sub> is a valine or a conservative substitution thereof.

23. (currently amended) The isolated polypeptide of claim 1, which has the amino acid sequence GDVCQDCIQMV (SEQ ID NO: 19).

24. (withdrawn)

25. (withdrawn)

26. (withdrawn)

27. (withdrawn)

28. (withdrawn)

29. (original) A method of treating a mammal, wherein said organism has a pathological condition associated to undesired angiogenesis, by administering an amount of an isolated polypeptide comprising a contiguous amino acid sequence DX1CX2D, wherein X1 and X2 are selected from the group consisting of amino acids, and said polypeptide has antiangiogenic activity, and wherein said amount of polypeptide is effective to reduce angiogenesis.

30. (original) The method of claim 29, wherein the mammal is human.
31. (original) The method of claim 29, wherein said pathological condition is cancer.
32. (original) The method of claim 31, wherein said cancer is Kaposi's Sarcoma.
33. (original) The method of claim 29, wherein administration is selected from the group consisting of subcutaneous, intramuscular, intravenous, intra-arterial, intrabronchial, oral, transdermal, intraocular, rectal, vaginal, intranasal, sublingual and intralesional.
34. (original) The method of claim 33, wherein the administration is selected from the group consisting of intralesional and transdermal
35. (original) The method of claim 29, wherein said isolated polypeptide is Saposin B.
36. (original) The method of claim 29, wherein said therapeutic amount is from about 0.1 mg/kg to about 20 mg/kg.
37. (original) A pharmaceutical composition in unit dosage form, which comprises:
- (a) one or more pharmaceutically acceptable excipients,
  - (b) an amount of a polypeptide comprising a contiguous amino acid sequence  $DX_1CX_2D$ , wherein  $X_1$  and  $X_2$  are selected from the group consisting of amino acids; and
- wherein the polypeptide is effective to treat or prevent undesired angiogenesis in an animal or patient to whom one or more unit doses of said composition are administered.
38. (original) The pharmaceutical composition of claim 37, wherein said unit dosage form is a topical ointment.

39. (original) The pharmaceutical composition of claim 37, wherein said unit dosage form is a topical ointment.

40. (original) An isolated fusion protein, said fusion protein comprising a polypeptide of a contiguous amino acid sequence  $DX_1CX_2D$ , wherein  $X_1$  and  $X_2$  are selected from the group consisting of amino acids, and a cell targeting moiety; wherein said cell targeting moiety and said polypeptide have functional activity independent of each other.

41. (original) The isolated fusion protein of claim 40, wherein said cell targeting moiety is a protein.

42. (original) The isolated fusion protein of claim 40, wherein said protein is an antibody.

Ab  
43. (original) The isolated fusion protein of claim 42, wherein said antibody is a monoclonal antibody.

44. (original) The isolated fusion protein of claim 43, wherein said antibody is a single chain Fv antibody.

45. (original) An isolated fusion protein, said fusion protein comprising a polypeptide of a contiguous amino acid sequence  $DX_1CX_2D$ , wherein  $X_1$  and  $X_2$  are selected from the group consisting of amino acids, and a cytotoxic moiety; wherein said cell targeting moiety and said polypeptide have functional activity independent of each other.

46. (original) The isolated fusion protein of claim 45, wherein said cytotoxic moiety is a protein.

47. (original) The isolated fusion protein of claim 45, wherein said protein is a bacterial toxin.

48. (original) The isolated fusion protein of claim 47, wherein said bacterial toxin is from Diphtheria.

49. (original) The isolated fusion protein of claim 48, wherein said bacterial toxin is the B chain of Diphtheria toxin.

Ab 50. (original) The isolated fusion protein of claim 47, wherein said bacterial toxin is from Pseudomonas.

51. (original) The isolated fusion protein of claim 50, wherein said bacterial toxin is Pseudomonas exotoxin.

52. (original) The isolated fusion protein of claim 51, wherein said Pseudomonas exotoxin is selected from the group consisting of PE38 and PE40.

---